The FDA last year turned away the companies' application and asked for additional efficacy data. Regeneron and Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent in ...

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

Revenue: Total revenue was $2.1 million for the quarter ended September 30, 2024, comprised of $0.6 million in net product ...

Journalist Annie Lowrey has a rare disease that causes a near-constant itch that doesn't respond to most treatments. She ...

Symptoms of viruses like COVID and flu overlap with each other, but there are ways you can narrow it down to get the ...

Emmeka Hawkins experienced itchy skin and bumps for over a year before she was diagnosed with chronic spontaneous urticaria.

In November 2021, however, she came up against a case nearly impossible to solve. It all started when Elisha woke up with an ...

Positive data from the phase 3 LIBERTY-CUPID Study C evaluating the investigational use of Dupixent (dupilumab) in biologic-naive patients with uncontrolled chronic spontaneous urticaria (CSU) who ...

(NASDAQ: REGN) and Sanofi will present positive data from the Phase 3 LIBERTY-CUPID Study C evaluating the investigational use of Dupixent ® (dupilumab) in biologic-naïve patients with uncontrolled ...

But on the other hand, it’s a brutal reckoning with chronic illnesses and postpartum ... Attack’ compares falling in love to needing an antihistamine, but it’s hard to feel anxious over ...

in patients with chronic spontaneous urticaria (CSU) who have not responded adequately to antihistamines. The results, presented at the American College of Allergy, Asthma & Immunology Annual ...